VJOncology is committed to improving our service to you

ESMO 2019 | PROMISE-meso: pembrolizumab vs. standard chemotherapy for mesothelioma

VJOncology is committed to improving our service to you

Sanjay Popat

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, provides and update on the (ETOP 9-15) PROMISE-meso trial (NCT02991482 ), a multicentre randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter